65 filings
8-K
JNCE
Jounce Therapeutics Inc
4 May 23
Termination of a Material Definitive Agreement
7:22am
8-K
JNCE
Jounce Therapeutics Inc
30 Mar 23
Departure of Directors or Certain Officers
4:08pm
8-K
JNCE
Jounce Therapeutics Inc
27 Mar 23
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
9:02am
8-K
JNCE
Jounce Therapeutics Inc
15 Mar 23
Other Events
6:21am
8-K
JNCE
Jounce Therapeutics Inc
13 Mar 23
Regulation FD Disclosure
6:30am
8-K
vw65g7bdq gm
23 Feb 23
Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking
6:11am
8-K
fx5n1xm2vh b5wou0di
20 Jan 23
Departure of Directors or Certain Officers
8:07am
8-K
z29ia176 1x
5 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
8-K
o1emhk jak
27 Dec 22
Entry into a Material Definitive Agreement
4:31pm
8-K
1v9n7ld7 q2
20 Dec 22
Departure of Directors or Certain Officers
7:21am
8-K
incy6dn1ivd
10 Nov 22
Jounce Therapeutics Reports Third Quarter 2022 Financial Results
7:17am
8-K
zfox9
30 Aug 22
Regulation FD Disclosure
8:07am
8-K
ynr9gegndsj uj6t
4 Aug 22
Jounce Therapeutics Reports Second Quarter 2022 Financial Results
7:13am
8-K
mft5 syecj2
27 Jun 22
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
b3a9c3m 75
5 May 22
Jounce Therapeutics Reports First Quarter 2022 Financial Results
7:07am
8-K
zza4li70i 6a1frv67z
7 Mar 22
Regulation FD Disclosure
7:06am
8-K
zq20r0p332deip
2 Mar 22
Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
7:06am
8-K
cfdmf8wvp58cob96nzc
10 Jan 22
Results of Operations and Financial Condition
7:31am
8-K
5mtjcfk vx
4 Nov 21
Entry into a Material Definitive Agreement
4:21pm
8-K
t4i2 9dnekxp
4 Nov 21
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
7:12am